Alpha-9 Theranostics announces C$11 million Series A financing

Torys acted as counsel to Longitude Capital with a team that included Cheryl Reicin and Brook Wong (financing/life sciences).

On April 28, 2021, Alpha-9 Theranostics Inc. announced an C$11 million Series A financing to advance a portfolio of novel radiotherapeutics and diagnostics. Longitude Capital led the financing with participation from BVF Partners L.P. and insiders.

Further information can be found on Globe Newswire’s website.

Alpha-9 Theranostics is a clinical stage, radiopharmaceutical company developing imaging and therapeutic molecules for solid and hematologic malignancies.

Longitude Capital is a leading healthcare venture capital firm that invests in transformative biotechnology, medical technology and health solutions companies seeking to improve clinical outcomes, enhance quality of life, and drive efficiency of healthcare delivery.